Immune Response to DENV

Total Page：16

File Type：pdf, Size：1020Kb

Learn More Dengue Clinical Case Management E-learning Immune Response to DENV DENV infected antigen presenting cells (APC) within the lymph node recruit T cells through the production of chemoattractants. The APCs process the foreign DENV proteins into small pieces for display on the cell surface. T cells that recognize the presented antigen become activated and produce pro-inflammatory mediators. This results in the activation of the two major branches of the adaptive immune response: • Humoral immunity: helper cells make pro-inflammatory mediators that activate B cells to make antibody to eliminate DENV • Cell-mediated immunity: cytotoxic T cells directly kill cells infected with DENV Development of Life-long Type Specific Immunity Soon after DENV infection, B cells become activated, proliferate and produce IgM against the infecting DENV type. Later, some B cells change to produce IgG (some IgA or IgE, too); however, the specificity of the antibody is the same. A subset of B cells become memory cells that provide life- long protection against the infecting DENV type. Serotype Cross-Reactivity in Dengue DENV types have similar envelope or E proteins so during infection, cross-reactive (heterotypic) antibodies against all DENV types are made. DENV types are immunologically distinct and induce the production of antibodies that are type-specific (homotypic). Centers for Disease Control and Prevention 1 National Center for Emerging and Zoonotic Infectious Diseases Learn More Dengue Clinical Case Management E-learning Immune Response to DENV Secondary DENV Infections If a person is re-infected with the same DENV type, memory B cells recognize it and will start to divide, resulting in the production of new B cells that make homotypic IgG and memory cells. The antibody can eliminate DENV so quickly that the person does not become noticeably ill. If a person has a second DENV infection with a new DENV type, the primary response is to make heterotypic antibodies against cross-reactive antigens to the first DENV type. This process is called original antigenic sin. Memory B cells are responsible for the production of these heterotypic antibodies. During this second exposure, virgin B cells will also produce homotypic antibodies against the infecting DENV type. Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases .

Copy Link

Recommended publications

Lactoferrin and Its Detection Methods: a Review
nutrients Review Lactoferrin and Its Detection Methods: A Review Yingqi Zhang, Chao Lu and Jin Zhang * Department of Chemical and Biochemical Engineering, University of Western Ontario, London, ON N6A 5B9, Canada; [email protected] (Y.Z.); [email protected] (C.L.) * Correspondence: [email protected] Abstract: Lactoferrin (LF) is one of the major functional proteins in maintaining human health due to its antioxidant, antibacterial, antiviral, and anti-inflammatory activities. Abnormal levels of LF in the human body are related to some serious diseases, such as inflammatory bowel disease, Alzheimer’s disease and dry eye disease. Recent studies indicate that LF can be used as a biomarker for diagnosis of these diseases. Many methods have been developed to detect the level of LF. In this review, the biofunctions of LF and its potential to work as a biomarker are introduced. In addition, the current methods of detecting lactoferrin have been presented and discussed. We hope that this review will inspire efforts in the development of new sensing systems for LF detection. Keywords: lactoferrin; biomarkers; immunoassay; instrumental analysis; sensor 1. Introduction Lactoferrin (known as lactotransferrin, LF), with a molecular weight of about 80 kDa, is a functional glycoprotein, which contains about 690 amino acid residues. It was first isolated from bovine milk by Sorensen in 1939 and was first isolated from human milk by Citation: Zhang, Y.; Lu, C.; Zhang, J. Johanson in 1960 [1,2]. The three-dimensional structure of LF has been unveiled by high Lactoferrin and Its Detection resolution X-ray crystallographic analysis, and it consists of two homologous globular lobes Methods: A Review.
[Show full text]
Monoclonal Antibody Playbook
Federal Response to COVID-19: Monoclonal Antibody Clinical Implementation Guide Outpatient administration guide for healthcare providers 2 SEPTEMBER 2021 1 Introduction to COVID-19 Monoclonal Antibody Therapy 2 Overview of Emergency Use Authorizations 3 Site and Patient Logistics Site preparation Patient pathways to monoclonal administration 4 Team Roles and Responsibilities Leadership Administrative Clinical Table of 5 Monoclonal Antibody Indications and Administration Indications Contents Preparation Administration Response to adverse events 6 Supplies and Resources Infrastructure Administrative Patient Intake Administration 7 Examples: Sites of Administration and Staffing Patterns 8 Additional Resources 1 1. Introduction to Monoclonal Therapy 2 As of 08/13/21 Summary of COVID-19 Therapeutics 1 • No Illness . Health, no infections • Exposed Asymptomatic Infected . Scope of this Implementation Guide . Not hospitalized, no limitations . Monoclonal Antibodies for post-exposure prophylaxis (Casirivimab + Imdevimab (RGN)) – EUA Issued. • Early Symptomatic . Scope of this Implementation Guide . Not hospitalized, with limitations . Monoclonal Antibodies for treatment (EUA issued): Bamlanivimab + Etesevimab1 (Lilly) Casirivimab + Imdevimab (RGN) Sotrovimab (GSK/Vir) • Hospital Adminission. Treated with Remdesivir (FDA Approved) or Tocilizumab (EUA Issued) . Hospitalized, no acute medical problems . Hospitalized, not on oxygen . Hospitlaized, on oxygen • ICU Admission . Hospitalized, high flow oxygen, non-invasive ventilation
[Show full text]
Ab200015 Human Lactoferrin Simplestep ELISA® Kit
Version 1 Last updated 28 August 2019 ab200015 Human Lactoferrin SimpleStep ELISA® Kit For the quantitative measurement of Lactoferrin in human serum, plasma, milk, urine, saliva, and cell culture supernatants. This product is for research use only and is not intended for diagnostic use. Copyright © 2018 Abcam. All rights reserved Table of Contents 1. Overview 1 2. Protocol Summary 2 3. Precautions 3 4. Storage and Stability 3 5. Limitations 4 6. Materials Supplied 4 7. Materials Required, Not Supplied 5 8. Technical Hints 5 9. Reagent Preparation 7 10. Standard Preparation 8 11. Sample Preparation 9 12. Plate Preparation 11 13. Assay Procedure 12 14. Calculations 14 15. Typical Data 15 16. Typical Sample Values 16 17. Assay Specificity 23 18. Species Reactivity 23 19. Troubleshooting 24 20. Notes 25 Technical Support 26 Copyright © 2018 Abcam. All rights reserved 1. Overview Lactoferrin in vitro SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Lactoferrin protein in humanserum, plasma, milk, urine, saliva, and cell culture supernatants. The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB Development Solution is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow.
[Show full text]
Tests for Autoimmune Diseases Test Codes 249, 16814, 19946
Tests for Autoimmune Diseases Test Codes 249, 16814, 19946 Frequently Asked Questions Panel components may be ordered separately. Please see the Quest Diagnostics Test Center for ordering information. 1. Q: What are autoimmune diseases? A: “Autoimmune disease” refers to a diverse group of disorders that involve almost every one of the body’s organs and systems. It encompasses diseases of the nervous, gastrointestinal, and endocrine systems, as well as skin and other connective tissues, eyes, blood, and blood vessels. In all of these autoimmune diseases, the underlying problem is “autoimmunity”—the body’s immune system becomes misdirected and attacks the very organs it was designed to protect. 2. Q: Why are autoimmune diseases challenging to diagnose? A: Diagnosis is challenging for several reasons: 1. Patients initially present with nonspecific symptoms such as fatigue, joint and muscle pain, fever, and/or weight change. 2. Symptoms often flare and remit. 3. Patients frequently have more than 1 autoimmune disease. According to a survey by the Autoimmune Diseases Association, it takes up to 4.6 years and nearly 5 doctors for a patient to receive a proper autoimmune disease diagnosis.1 3. Q: How common are autoimmune diseases? A: At least 30 million Americans suffer from 1 or more of the 80 plus autoimmune diseases. On average, autoimmune diseases strike three times more women than men. Certain ones have an even higher female:male ratio. Autoimmune diseases are one of the top 10 leading causes of death among women age 65 and under2 and represent the fourth-largest cause of disability among women in the United States.3 Women’s enhanced immune system increases resistance to infection, but also puts them at greater risk of developing autoimmune disease than men.
[Show full text]
Understanding the Immune System: How It Works
Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
[Show full text]
Datasheet: MCA2763 Product Details
Datasheet: MCA2763 Description: MOUSE ANTI HUMAN LACTOFERRIN Specificity: LACTOFERRIN Format: Purified Product Type: Monoclonal Antibody Clone: 2B8 Isotype: IgG1 Quantity: 0.2 mg Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Flow Cytometry Immunohistology - Frozen Immunohistology - Paraffin ELISA Immunoprecipitation Western Blotting Functional Assays Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls. Target Species Human Product Form Purified IgG - liquid Preparation Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN ) Stabilisers 3 Approx. Protein 1.0mg/ml Concentrations Immunogen Purified Lactoferrin from human milk. External Database UniProt: Links P02788 Related reagents Page 1 of 3 Entrez Gene: 4057 LTF Related reagents Synonyms LF Fusion Partners Spleen cells from immunised Balb/c mice were fused with cells of the Sp2/0 myeloma cell line. Specificity Mouse anti Human Lactoferrin antibody, clone 2B8 recognizes human lactoferrin, a ~80 kDa globular iron binding glycoprotein found in body secretions such as milk and saliva and is a member of the transferrin family proteins.
[Show full text]
Coverage of Monoclonal Antibody Products to Treat COVID-19
Coverage of Monoclonal Antibody Products to Treat COVID-19 Monoclonal antibody products to treat Coronavirus disease 2019 (COVID-19) help the body fight the virus or slow the virus’s growth. Medicare beneficiaries have coverage without beneficiary cost sharing for these products when used as authorized or approved by the Food and Drug Administration (FDA). Disclaimer: The contents of this document do not have the force and effect of law and are not meant to bind the public Medicare in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. This communication was printed, published, or produced and disseminated at U.S. taxpayer expense. Site of Care1 Payable by Expected Patient Expected Payment to Providers: Medicare Cost-Sharing Key Facts • Medicare payment for monoclonal antibody products to treat COVID-19 is similar across Inpatient No patient sites of care, with some small differences. Hospital cost-sharing • Medicare pays for the administration of monoclonal antibody products to treat COVID-19. For example, beginning on May 6, 2021, Medicare will pay approximately Outpatient $450 in most settings, or approximately $750 No patient in the beneficiary’s home or residence, for Hospital or cost-sharing the administration of certain monoclonal “Hospital 4 2 antibody products to treat COVID-19. For without Walls ” monoclonal antibody products to treat COVID-19 that are administered before May 6, 2021, the Medicare payment rate in all No patient settings is approximately $310. Outpatient cost-sharing3 Physician Office/ • CMS will exercise enforcement discretion to Infusion Center allow Medicare-enrolled immunizers working within their scope of practice and subject to applicable state law to bill directly and receive direct reimbursement from the Medicare program for administering Nursing Home monoclonal antibody treatments to No patient (See third bullet in Medicare Part A Skilled Nursing Facility Key Facts on CMS cost-sharing residents.
[Show full text]
Monoclonal Antibody Treatment for COVID-19
Monoclonal Antibody Treatment for COVID-19 Monoclonal antibody treatment is for people who have COVID-19 or were recently exposed to someone who has COVID-19, and are not hospitalized. Treatment can lower the amount of virus in your body, reduce symptoms and help avoid hospitalization. Treatment works best when you get it soon after COVID-19 symptoms begin, so it is important to get tested right away. What is monoclonal antibody treatment? How is monoclonal antibody Monoclonal antibodies are made in a lab and treatment given? work similarly to antibodies your immune Treatment is usually given by intravenous (IV) system makes to fight infection. Monoclonal infusion and takes about an hour. Treatment can antibody treatment helps your body fight also be given by injection. Patients are observed COVID-19 while your immune system begins for an additional hour to make sure they do not to make its own antibodies. In clinical studies, have any immediate bad reactions. monoclonal antibody treatments were shown to be safe and effective. What are the side effects? Side effects may include: Who is eligible for monoclonal antibody treatment? • A reaction at the site of the IV or injection, including pain, swelling, bleeding or bruising Treatment is authorized for people who meet all the following: • Nausea, vomiting or diarrhea • Itching, rash or hives Tested positive for COVID-19 Have had mild to moderate COVID-19 Allergic reactions and other serious side effects symptoms for 10 days or less are very rare. If you experience fever, trouble breathing, rapid or slow heart rate, tiredness, Are age 12 or older and weigh at least 88 pounds weakness, confusion, or other concerning symptoms, contact your provider right away.
[Show full text]
Original Antigenic Sin: a Comprehensive Review
Journal of Autoimmunity 83 (2017) 12e21 Contents lists available at ScienceDirect Journal of Autoimmunity journal homepage: www.elsevier.com/locate/jautimm Review article Original antigenic sin: A comprehensive review Anup Vatti a, Diana M. Monsalve b, Yovana Pacheco b, Christopher Chang a, * Juan-Manuel Anaya b, M. Eric Gershwin a, a University of California at Davis, Division of Rheumatology, Allergy and Clinical Immunology, Suite 6501, 451 Health Sciences Drive, Davis, CA, 95616, USA b Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 No. 63-C-69, Bogota, Colombia article info abstract Article history: The concept of “original antigenic sin” was ﬁrst proposed by Thomas Francis, Jr. in 1960. This phe- Received 27 March 2017 nomenon has the potential to rewrite what we understand about how the immune system responds to Received in revised form infections and its mechanistic implications on how vaccines should be designed. Antigenic sin has been 24 April 2017 demonstrated to occur in several infectious diseases in both animals and humans, including human Accepted 25 April 2017 inﬂuenza infection and dengue fever. The basis of “original antigenic sin” requires immunological Available online 5 May 2017 memory, and our immune system ability to autocorrect. In the context of viral infections, it is expected that if we are exposed to a native strain of a pathogen, we should be able to mount a secondary immune Keywords: “ ” Vaccination response on subsequent exposure to the same pathogen. Original antigenic sin will not contradict this Bocavirus well-established immunological process, as long as the subsequent infectious antigen is identical to the Dengue original one.
[Show full text]
Vaccine Immunology Claire-Anne Siegrist
2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
[Show full text]
Monitoring Multiple Myeloma Patients Treated with Daratumumab: Teasing out Monoclonal Antibody Interference
Clin Chem Lab Med 2016; 54(6): 1095–1104 Open Access Christopher McCuddena, Amy E. Axela, Dominique Slaets, Thomas Dejoie, Pamela L. Clemens, Sandy Frans, Jaime Bald, Torben Plesner, Joannes F.M. Jacobs, Niels W.C.J. van de Donk, Philippe Moreau, Jordan M. Schecter, Tahamtan Ahmadi and A. Kate Sasser* Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference DOI 10.1515/cclm-2015-1031 developed using a mouse anti-daratumumab antibody. To Received October 21, 2015; accepted February 10, 2016; previously evaluate whether anti-daratumumab bound to and shifted published online March 30, 2016 the migration pattern of daratumumab, it was spiked into Abstract daratumumab-containing serum and resolved by IFE/SPE. The presence (DIRA positive) or absence (DIRA negative) Background: Monoclonal antibodies are promising anti- of residual M-protein in daratumumab-treated patient myeloma treatments. As immunoglobulins, monoclonal samples was evaluated using predetermined assessment antibodies have the potential to be identified by serum criteria. DIRA was evaluated for specificity, limit of sensi- protein electrophoresis (SPE) and immunofixation elec- tivity, and reproducibility. trophoresis (IFE). Therapeutic antibody interference with Results: In all of the tested samples, DIRA distinguished standard clinical SPE and IFE can confound the use of between daratumumab and residual M-protein in com- these tests for response assessment in clinical trials and mercial serum samples spiked with daratumumab and disease monitoring. in daratumumab-treated patient samples. The DIRA Methods: To discriminate between endogenous myeloma limit of sensitivity was 0.2 g/L daratumumab, using protein and daratumumab, a daratumumab-specific spiking experiments. Results from DIRA were repro- immunofixation electrophoresis reflex assay (DIRA) was ducible over multiple days, operators, and assays.
[Show full text]
B Cell Responses Against Influenza Viruses
viruses Review B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat Jenna J. Guthmiller 1,* , Henry A. Utset 1 and Patrick C. Wilson 1,2 1 Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA; [email protected] (H.A.U.); [email protected] (P.C.W.) 2 Committee on Immunology, University of Chicago, Chicago, IL 60637, USA * Correspondence: [email protected] Abstract: Antibodies are critical for providing protection against influenza virus infections. However, protective humoral immunity against influenza viruses is limited by the antigenic drift and shift of the major surface glycoproteins, hemagglutinin and neuraminidase. Importantly, people are exposed to influenza viruses throughout their life and tend to reuse memory B cells from prior exposure to generate antibodies against new variants. Despite this, people tend to recall memory B cells against constantly evolving variable epitopes or non-protective antigens, as opposed to recalling them against broadly neutralizing epitopes of hemagglutinin. In this review, we discuss the factors that impact the generation and recall of memory B cells against distinct viral antigens, as well as the immunological limitations preventing broadly neutralizing antibody responses. Lastly, we discuss how next-generation vaccine platforms can potentially overcome these obstacles to generate robust and long-lived protection against influenza A viruses. Keywords: influenza viruses; humoral immunity; broadly neutralizing antibodies; imprinting; Citation: Guthmiller, J.J.; Utset, H.A.; hemagglutinin; germinal center; plasma cells Wilson, P.C. B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat. Viruses 2021, 13, 1.
[Show full text]